The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
With the NHI price listing of its Crohn’s disease cell therapy Alofisel (darvadstrocel) this month, Takeda Pharmaceutical now has three products in its gastrointestinal specialty franchise in Japan. The company is set to capitalize on these products to grow its…
To read the full story
Related Article
- Takeda Rolls Out Crohn’s Disease Cell Therapy Alofisel in Japan
December 1, 2021
- Takeda’s Cell Therapy Alofisel Approved in Japan
September 28, 2021
- 1st Drug for Short Bowel Syndrome Now Available in Japan: Takeda
August 19, 2021
BUSINESS
- Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
- Quviviq Retains Top Slot in Rep Calls for GPs: Intage March Data
May 16, 2025
- ASKA Filed Switched OTC of Emergency Contraceptive Last June
May 16, 2025
- Fujifilm Seeks Japan Nod for Stem Cell Therapy for Meniscus Injuries
May 15, 2025
- Tecentriq Filed for Thymic Carcinoma in Japan: Chugai
May 15, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…